Skip to content

Evaluation of the efficacy of Yinqiao Baiyi Decoction for asymptomatic patients infected with COVID-19

Evaluation of the efficacy of Yinqiao Baiyi Decoction for asymptomatic patients infected with COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006748
Enrollment
Unknown
Registered
2022-11-05
Start date
2022-11-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The First Affiliated Hospital to Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Asymptomatic patients with COVID-19; ? Age 18-80 years old; ? Voluntarily accept treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: ? delirious, consciousness disorder, dementia, all kinds of mental patients; ? Pregnant and lactating women; ? Patients with active pulmonary tuberculosis, pulmonary abscess and chronic respiratory failure; ? Patients with tumor; ? Patients with severe liver and kidney diseases; ? patients with severe cardiovascular and cerebrovascular diseases; ? those who are taking part in clinical trials of other drugs and are known to be allergic to the treatment drugs.

Design outcomes

Primary

MeasureTime frame
Nucleic acid conversion rate;Nucleic acid turning negative time;

Secondary

MeasureTime frame
Time to change to light/normal;Incidence of symptoms;Cumulative incidence of adverse events;rate to light/normal;

Countries

China

Contacts

Public ContactLi Suyun
lisuyun2000@126.com0371-66248624

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026